GlaxoSmithKline Pharmaceuticals Limited — Cyborg Score 6/10

Solid
Pharmaceuticals

Strategic Profile

Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. It also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, and others. The company leverages a strong distribution and manufacturing infrastructure to serve diverse patient populations across India.

Cyborg Score Rationale

GSK India maintains a leading market position with diversified portfolio spanning general medicines, vaccines, and specialty medicines across respiratory and oncology. However, revenue growth has been modest (5.49% CAGR over five years as of July 2026), and market capitalization has declined significantly, indicating challenges in competitive positioning.

Top Insights

  • GSK has a head office in Mumbai with a manufacturing facility at Nashik in Maharashtra, 20 Contract Manufacturing Organisations.
  • The company's product portfolio includes prescription medicines and vaccines.
  • The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology.
  • The company maintains significant distribution reach through 26 warehouses and 6,000 stockists across India as of July 2026.

Named Competitors

  • Cipla — Leading Indian pharmaceutical company with diversified portfolio
  • Lupin — Major Indian pharma player with global presence
  • Aurobindo — Significant player in generic and branded pharmaceuticals
  • Sun Pharma — Major Indian multinational pharma company

Recent Developments

  • As of July 2026, GSK India operates with a market capitalization of approximately ₹40,581 crores and revenue of ₹3,822 crores, reflecting modest historical growth patterns.

Open the full interactive GlaxoSmithKline Pharmaceuticals Limited report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →